D. Dehn

发表

Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems*

David Siegel, David Ross, J. Pietenpol, 2003, The Journal of Biological Chemistry.

NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.

L. Berliner, D. Ross, D. Dehn, 2004, Molecular pharmacology.

NAD(P)H:quinone Oxidoreductase 1-Compromised Human Bone Marrow Endothelial Cells Exhibit Decreased Adhesion Molecule Expression and CD34+ Hematopoietic Cell Adhesion

D. Ross, D. Dehn, D. Siegel, 2010, Journal of Pharmacology and Experimental Therapeutics.

5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo

D. Ross, D. Dehn, D. Siegel, 2006, Molecular Cancer Therapeutics.

NQO1-COMPROMISED HUMAN BONE MARROW ENDOTHELIAL CELLS EXHIBIT DECREASED ADHESION MOLECULE EXPRESSION AND CD34+ HEMATOPOIETIC CELL ADHESION

D. Dehn, D. Siegel, J. Kepa, 2010 .

B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration.

K. Shroyer, T. Enomoto, D. Dehn, 2007, Gynecologic oncology.

RH1 Induces Cellular Damage in an NAD(P)H:Quinone Oxidoreductase 1-Dependent Manner: Relationship between DNA Cross-linking, Cell Cycle Perturbations, and Apoptosis

D. Ross, D. Dehn, S. Inayat-Hussain, 2005, Journal of Pharmacology and Experimental Therapeutics.

Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90.

David Siegel, William Lewis, Chrisostomos Prodromou, 2013, Nature chemistry.

Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems.

D. Ross, D. Dehn, D. Siegel, 2003, Molecular pharmacology.

Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.

D. Ross, D. Dehn, C. Moody, 2001, Biochemical pharmacology.

p16INK4a is superior to high‐risk human papillomavirus testing in cervical cytology for the prediction of underlying high‐grade dysplasia

Matthew A. Titmus, Meenakshi Singh, K. Shroyer, 2010, Cancer cytopathology.

Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma

K. Shroyer, D. Dehn, K. Torkko, 2007, Cancer.

NQO1 Expression in Pancreatic Cancer and Its Potential Use as a Biomarker

K. Shroyer, R. Shah, D. Dehn, 2007, Applied immunohistochemistry & molecular morphology : AIMM.

Development of a New Isogenic Cell-Xenograft System for Evaluation of NAD(P)H:Quinone Oxidoreductase-Directed Antitumor Quinones

D. Ross, D. Dehn, S. Winski, 2004, Clinical Cancer Research.

Screening for molecular markers of cervical papillomavirus infection: overview of methods and their clinical implications.

K. Shroyer, D. Dehn, D. Malinowski, 2009, Methods in molecular biology.

Human Papillomavirus Testing in Cervical Cytology for the Prediction of Underlying High-Grade Dysplasia

Matthew A. Titmus, Meenakshi Singh, K. Shroyer, 2010 .